DiscGenics Company Update
April 30, 2018
Dear Friends of DiscGenics,
We officially commenced clinical evaluation of IDCT for degenerative disc disease last month, and just yesterday, announced the first patient has been treated in our U.S. Phase I/II trial. This is a critical milestone, as the study will not only help advise us on the safety and tolerability of IDCT at varying dosage levels, but will begin to give us some insight into the potential effect of IDCT on lower back pain and disability.
In addition, we presented data from two animal studies at the Orthopedic Research Society (ORS) Annual Meeting held last month in New Orleans. The studies highlighted the safety and regenerative capacity of Discogenic Cells, which are the active ingredient in IDCT.
I invite you to review these and the additional items below and contact us if you have any questions.
As always, I would like to thank you on behalf of the entire DiscGenics team for your interest and support, and look forward to updating you on our continued efforts to transform the way millions of patients suffering from the debilitating effects of chronic back pain are treated.
Sincerely,
Flagg Flanagan
Chief Executive Officer and Chairman of the Board
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
